化学療法による吐き気と嘔吐（CINV）の世界市場レポート 2025年

化学療法による吐き気と嘔吐（CINV）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.5％で42億米ドルに成長します。予測期間の成長は、個別化医療、制吐剤の進歩、遠隔医療と遠隔モニタリング、健康公平性への取り組みに起因します。予測期間の主な動向には、制吐剤の併用療法、支持療法サービス、デジタルヘルスツール、サバイバーシップケアなどがあります。

がんの罹患率の増加は、当面の化学療法による吐き気と嘔吐（CINV）市場の拡大を牽引するとみられます。がんの増殖は、体内の特定の細胞が制御不能な成長を遂げ、体内の他の部位に転移することで発生します。がん患者が増加する中、化学療法の副作用であるCINVを緩和するため、より効果的で的を絞った制吐療法の開発が急がれています。このようにCINVの管理に対する関心が高まるにつれ、その根本的なメカニズムの解明が進み、革新的な治療法が生み出されています。例えば、2023年1月現在、米国がん協会（ACS）は、2023年の米国における新規がん罹患者数は約190万人（1日当たり約5,370人）、がん関連死亡者数は609,820人（1日当たり約1,670人）と予測しています。その結果、がんの有病率の増加が化学療法による吐き気と嘔吐（CINV）市場の原動力となります。

化学療法による吐き気と嘔吐（CINV）市場の成長は、有利な規制イニシアチブの増加によって牽引されると予想されます。規制イニシアチブとは、規制機関が規制を策定、施行、実施するために行う行動のことです。これらのイニシアチブは、ガイドラインやポリシーを確立することにより、化学療法による吐き気と嘔吐（CINV）の予防と管理を強化することを目的としています。例えば、2024年10月、公衆衛生保護に重点を置く連邦機関である米国食品医薬品局（FDA）は、その医薬品評価研究センター（CDER）が2023年に、化学療法による吐き気と嘔吐（CINV）に特化した55の新薬を承認したと報告しました。その結果、CINV市場の成長を後押ししているのは、規制当局の有利なイニシアチブの高まりです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界化学療法による吐き気と嘔吐（CINV） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の化学療法による吐き気と嘔吐（CINV）市場：成長率分析
• 世界の化学療法による吐き気と嘔吐（CINV）市場の実績：規模と成長, 2019-2024
• 世界の化学療法による吐き気と嘔吐（CINV）市場の予測：規模と成長, 2024-2029, 2034F
• 世界化学療法による吐き気と嘔吐（CINV）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の化学療法による吐き気と嘔吐（CINV）市場：形態別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射剤
• オーラル
• 経皮パッチ
• 世界の化学療法による吐き気と嘔吐（CINV）市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 5-HT3受容体拮抗薬
• ニューロキニン-1受容体拮抗薬
• コルチコステロイド
• カンナビノイド
• その他の薬物クラス
• 世界の化学療法による吐き気と嘔吐（CINV）市場催吐性リスク、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高度催吐性化学療法（HEC）
• 中等度の催吐性化学療法（MEC）
• 低催吐性化学療法（LEC）
• 世界の化学療法による吐き気と嘔吐（CINV）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• CINV病院
• がん調査
• 小売薬局
• オンライン薬局
• ドラッグストア
• 世界の化学療法による吐き気と嘔吐（CINV）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 婦人科
• 泌尿器科
• 消化器外科
• その他の用途
• 世界の化学療法による吐き気と嘔吐（CINV）市場、注射剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内（IV）溶液
• 筋肉内（IM）注射
• 世界の化学療法による吐き気と嘔吐（CINV）市場、口腔のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• カプセル
• 液体製剤
• 世界の化学療法による吐き気と嘔吐（CINV）市場経皮吸収パッチの種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェンタニルパッチ
• スコポラミンパッチ

第7章 地域別・国別分析

• 世界の化学療法による吐き気と嘔吐（CINV）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の化学療法による吐き気と嘔吐（CINV）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 化学療法による吐き気と嘔吐（CINV）市場：競合情勢
• 化学療法による吐き気と嘔吐（CINV）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• GlaxoSmithKline plc
• Baxter International Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bausch Health Companies Inc.
• Eisai Co. Ltd.
• Jazz Pharmaceuticals plc
• Ono Pharmaceutical Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Kyowa Kirin Inc.
• Amneal Pharmaceuticals Inc.
• Mundipharma International Limited
• Insys Therapeutics Inc.
• Lupin Limited
• Helsinn Holding S.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 化学療法による吐き気と嘔吐（CINV）市場2029：新たな機会を提供する国
• 化学療法による吐き気と嘔吐（CINV）市場2029：新たな機会を提供するセグメント
• 化学療法による吐き気と嘔吐（CINV）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chemotherapy-induced nausea and vomiting (CINV) is a condition characterized by the sensation of nausea and vomiting, often arising as a side effect of chemotherapy treatment. This common side effect can significantly impact the quality of life and treatment outcomes for many cancer patients. Fortunately, CINV can be effectively managed and treated through medications and lifestyle adjustments.

CINV presents in various forms, including injectables, oral medications, and transdermal patches. Injectables are chemical substances administered via injection to produce various therapeutic effects. Medications used for CINV management belong to different drug classes, such as 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids, and others. The risk of developing CINV varies, with emetogenic risks categorized into highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC), and low emetogenic chemotherapy (LEC). These treatments and medications are distributed through multiple channels, including CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies, and drug stores. They find application in various medical fields such as gynecology, urology, gastrointestinal surgery, and others.

The chemotherapy-induced nausea and vomiting (CINV) market research report is one of a series of new reports from The Business Research Company that provides chemotherapy-induced nausea and vomiting (CINV) market statistics, including chemotherapy-induced nausea and vomiting (CINV) industry global market size, regional shares, competitors with a chemotherapy-induced nausea and vomiting (CINV) market share, detailed chemotherapy-induced nausea and vomiting (CINV) market segments, market trends and opportunities and any further data you may need to thrive in the chemotherapy-induced nausea and vomiting (CINV) industry. This chemotherapy-induced nausea and vomiting (CINV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy-induced nausea and vomiting (CINV) market size has grown strongly in recent years. It will grow from $2.92 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.

The chemotherapy-induced nausea and vomiting (CINV) market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.

The increasing incidence of cancer is set to drive the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the foreseeable future. The proliferation of cancer occurs when certain cells in the body undergo uncontrolled growth and spread to other parts of the body. With cancer cases on the rise, there is a growing impetus to develop more effective and targeted antiemetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on managing CINV has led to advancements in understanding its underlying mechanisms and the creation of innovative therapies. For example, as of January 2023, the American Cancer Society (ACS) anticipates around 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer-related deaths (about 1,670 deaths per day) in the United States for 2023. Consequently, the increasing prevalence of cancer will be a driving force behind the chemotherapy-induced nausea and vomiting (CINV) market.

The growth of the chemotherapy-induced nausea and vomiting (CINV) market is expected to be driven by the increasing favorable regulatory initiatives. Regulatory initiatives are actions undertaken by regulatory bodies to develop, enforce, or implement regulations. These initiatives are aimed at enhancing the prevention and management of chemotherapy-induced nausea and vomiting (CINV) by establishing guidelines and policies. For example, in October 2024, the U.S. Food and Drug Administration (FDA), a federal agency focused on public health protection, reported that in 2023, its Center for Drug Evaluation and Research (CDER) approved 55 new drugs specifically for chemotherapy-induced nausea and vomiting (CINV). As a result, the growing favorable regulatory initiatives are propelling the growth of the CINV market.

Major companies in the chemotherapy-induced nausea and vomiting (CINV) market are focusing on new product innovations, such as fixed intravenous antiemetics, to gain a competitive edge. A fixed intravenous antiemetic refers to a predetermined dose of medication delivered via IV to prevent or treat nausea and vomiting, commonly used in chemotherapy or post-surgery contexts. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical manufacturer, launched AKYNZEO I.V. in India, the first fixed intravenous antiemetic combination designed to prevent chemotherapy-induced nausea and vomiting (CINV). This product combines netupitant and palonosetron, addressing both acute and delayed phases of nausea and vomiting. It offers single-dose convenience, higher complete response rates, and improved quality of life for cancer patients. Clinical studies indicate it is especially effective for patients undergoing highly emetogenic chemotherapy.

In January 2022, Cumberland Pharmaceuticals Inc., a U.S.-based specialty pharmaceutical firm, acquired SANCUSO (granisetron transdermal patch) from Kyowa Kirin Inc. for $13.5 million. This acquisition granted Cumberland full control over the U.S. rights to SANCUSO, a chemotherapy-induced nausea and vomiting (CINV) drug. This included responsibility for marketing, promotion, distribution, manufacturing, and medical support operations related to the product. Kyowa Kirin Inc. is a U.S.-based subsidiary of Kyowa Kirin Co. Ltd. in Japan, a specialty pharmaceutical company that specializes in developing innovative medicines used for preventing CINV.

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chemotherapy-induced nausea and vomiting (CINV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy-induced nausea and vomiting (CINV) market consists of revenues earned by entities by providing services such as pharmacologic therapy and nonpharmacologic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced nausea and vomiting (CINV) market also includes the sales of such as olanzapine, dexamethasone, cannabinoids, metoclopramide, promethazine and prochlorperazine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy-induced nausea and vomiting (cinv) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy-induced nausea and vomiting (cinv) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chemotherapy-induced nausea and vomiting (cinv) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Form: Injectables; Oral; Transdermal Patches
• 2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class
• 3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
• 4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
• 5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications
• Subsegments:
• 1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections
• 2) By Oral: Tablets; Capsules; Liquid Formulations
• 3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Characteristics

3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies

4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Rate Analysis
• 5.4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Total Addressable Market (TAM)

6. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segmentation

• 6.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Oral
• Transdermal Patches
• 6.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5-HT3 Receptor Antagonists
• Neurokinin-1 Receptor Antagonists
• Corticosteroids
• Cannabinoids
• Other Drug Class
• 6.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Highly Emetogenic Chemotherapy (HEC)
• Moderately Emetogenic Chemotherapy (MEC)
• Low Emetogenic Chemotherapy (LEC)
• 6.4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CINV Hospitals
• Cancer Research Institute
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• 6.5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gynecology
• Urology
• Gastrointestinal Surgery
• Other Applications
• 6.6. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Injectables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Solutions
• Intramuscular (IM) Injections
• 6.7. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Liquid Formulations
• 6.8. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Transdermal Patches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fentanyl Patches
• Scopolamine Patches

7. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Regional And Country Analysis

• 7.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 8.1. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 9.1. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 9.2. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 10.1. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 11.1. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 11.2. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 12.1. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 13.1. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 14.1. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 14.2. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 15.1. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 15.2. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 16.1. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 17.1. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 18.1. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 19.1. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 20.1. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 21.1. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 21.2. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 22.1. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 23.1. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 23.2. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 24.1. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 24.2. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 25.1. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 25.2. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 26.1. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 26.2. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 27.1. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 28.1. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 28.2. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 29.1. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 29.2. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Landscape And Company Profiles

• 30.1. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Landscape
• 30.2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. GlaxoSmithKline plc
• 31.3. Baxter International Inc.
• 31.4. Teva Pharmaceuticals Industries Ltd.
• 31.5. Bausch Health Companies Inc.
• 31.6. Eisai Co. Ltd.
• 31.7. Jazz Pharmaceuticals plc
• 31.8. Ono Pharmaceutical Co. Ltd.
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. Kyowa Kirin Inc.
• 31.11. Amneal Pharmaceuticals Inc.
• 31.12. Mundipharma International Limited
• 31.13. Insys Therapeutics Inc.
• 31.14. Lupin Limited
• 31.15. Helsinn Holding S.A.

32. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market

34. Recent Developments In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market

35. Chemotherapy-Induced Nausea and Vomiting (CINV) Market High Potential Countries, Segments and Strategies

• 35.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer